Halozyme Could Get $83M in Licensing Deal

Xconomy San Diego — 

San Diego’s Halozyme Therapeutics (NASDAQ: HALO) says it will receive an upfront payment of $9 million and potential future milestone payments of $74 million under an exclusive worldwide licensing agreement with Exton, PA-based ViroPharma (NASDAQ: VPHM). Halozyme is licensing the use of its recombinant human hyaluronidase in the development of a subcutaneous formulation of human C1 esterase inhibitor. ViroPharma develops proprietary pharmaceuticals to treat influenza, viral Pneumonia, Hepatits C, and other viral diseases.